[HTML][HTML] Predictors of health utility in relapsing–remitting and secondary-progressive multiple sclerosis: implications for future economic models of disease-modifying …
L Hernandez, M O'Donnell, M Postma, MSOAC - PharmacoEconomics, 2021 - Springer
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
[HTML][HTML] Predictors of Health Utility in Relapsing–Remitting and Secondary‑Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease …
L Hernandez, M O'Donnell, M Postma - PharmacoEconomics, 2021 - search.proquest.com
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying …
L Hernandez, M O'Donnell, M Postma - PharmacoEconomics, 2021 - ideas.repec.org
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying …
L Hernandez, M O'Donnell… - …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying …
L Hernandez, M O'Donnell, M Postma - PharmacoEconomics, 2021 - econpapers.repec.org
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying …
L Hernandez, M O'Donnell, M Postma - Pharmacoeconomics, 2021 - research.rug.nl
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …
[HTML][HTML] Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease …
L Hernandez, M O'Donnell, M Postma - Pharmacoeconomics, 2021 - ncbi.nlm.nih.gov
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
Predictors of Health Utility in Relapsing–Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying …
L Hernandez, M O'Donnell… - …, 2021 - search.ebscohost.com
Background: Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing–remitting multiple sclerosis (RRMS) have characterized disease …
Predictors of Health Utility in Relapsing-Remitting and Secondary-Progressive Multiple Sclerosis: Implications for Future Economic Models of Disease-Modifying …
L Hernandez, M O'Donnell, M Postma - Pharmacoeconomics, 2020 - europepmc.org
Background Decision-analytic models used in economic evaluations of disease-modifying
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …
therapies for relapsing-remitting multiple sclerosis (RRMS) have characterized disease …